Immunotoxins: Promising Anticancer Drugs with Improved Potency and Selectivity

The potential of immunotoxins for the treatment of cancer has not yet been realized owing to the difficulty of delivering therapeutic concentrations of these drugs to the target cells. In an effort to overcome this problem we have synthesized immunotoxins that have 100- to 1000-fold higher cytotoxic potency than clinically used anticancer drugs. These immunotoxins are linked to antibodies via disulfide bonds, which ensures the release of fully active drug inside the cells. The conjugates show high antigen-specific cytotoxicity for cultured human cancer cells (50% inhibiting concentration, 10 to 40 pm), low systemic toxicity in mice, and good pharmacokinetic behavior.

INTRODUCTION

Numerous attempts to target tumors with conventional antineoplastic drugs conjugated to monoclonal antibodies have met with limited success. Most frequently, such antibody-drug conjugates are insufficiently cytotoxic, e.g., the conjugates are even less potent than the nonconjugated drugs (1-3). In contrast, a number of antibody conjugates with single chain ribosome-inactivating protein toxins or with isolated A-chains of two chain ribosome-inactivating protein toxins, such as ricin, have been prepared (4, 5) that are at least 103-fold more cytotoxic than conjugates between antibodies and antineoplastic drugs (1-3). Conjugates between antibodies and protein toxins are also much more potent than the corresponding nonconjugated toxins.

One reason for the different efficacy of these two classes of immunotoxins may lie in the different modes of action of their toxic moieties. Protein toxins act catalytically, and it has been demonstrated that a single toxin molecule in the cytoplasm of a cell can cause the death of that cell (6, 7). In contrast, anticancer drugs currently in clinical use, such as doxorubicin, methotrexate, and the Vinca alkaloids, act stoichiometrically, and relatively much higher intracellular concentrations are needed to achieve comparable cytotoxicities. Intracellular concentrations of drug necessary to kill the target cells are difficult to achieve with antibody-drug conjugates for the following reasons: (a) a majority of commonly used anticancer drugs are only moderately cytotoxic; (b) antigen targets are present on cell surfaces often in only limited numbers (8); (c) the internalization processes for antigen-antibody complexes are frequently inefficient; and (d) most linkers that have been used for the conjugation of drugs to antibodies (1-3, 9-14) do not efficiently release active drug inside the cell.

We describe here an approach that seeks to overcome these problems by replacing the current anticancer drug candidates with compounds of 100- to 1000-fold higher cytotoxicity, and by conjugating these compounds with antibodies via disulfide-containing linkers that can be cleaved inside the cell to release active drug.

MATERIALS AND METHODS

Maytansine and Maytansinoids. Maytansine (1) is a product of Takeda Chemical Industries, Ltd. (Japan). Ansamitocin P-3, a precursor that was used to synthesize maytansinoid 2 (Fig. 2) was supplied by the Antibody Research Center of Takeda Chemical Industries, Japan. Synthesis of maytansinoid 2 was performed as follows: Maytansin or ansamitocin P-3 was reduced with lithium aluminum hydride to give the same C-3 alcohol maytansinol as previously described (15). Maytansinol was esterified with N-methyl-N-(methylthio)propanoyl to give maleimido maytansinoid 2, which was purified by column chromatography on silica gel eluting with 6% methanol in chloroform. This synthesis will be described in detail elsewhere.

Antibodies. Murine monoclonal antibody A7 that binds to an antigen expressed on human colon cancer cell lines (16) was a generous gift of Dr. Takahashi (Kyoto University, Kyoto, Japan). The production of the murine monoclonal antibody TA.1 that binds to the HER-2/neu oncogene protein has been described elsewhere (17). Murine monoclonal antibodies 5E9 (anti-human transferrin receptor) and anti-B4 (anti-CD19) were purified by methods described previously (8, 18).

Conjugation of Maytansinoids with Antibodies. In order to generate antibody-maytansinoid conjugates, the antibody was modified with N-succinimidyl-3-(2-pyridyldithio)propionate to introduce thiopyridyl groups, or with succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate to introduce maleimido groups. May-SS-Me2 was reduced to May-SH © by the following procedure. A solution of 2 (2 mM) in a mixture of ethanol (0.3 ml) and 50 mM potassium phosphate buffer (0.2 ml; pH 7.5) was treated with diithiothreitol (3 mM) at 4°C for 4 h under nitrogen. The freshly prepared May-SH 2 was purified by high-pressure liquid chromatography and characterized by high-resolution nuclear magnetic resonance analysis. The product (1.2 equivalents per antibody) was subjected to a Sephadex G-25 column. Modification of the antibody to a different extent with N-succinimidyl-3-(2-pyridyldithio)propionate gave 1 to 6 thiopyridyl groups per antibody molecule (as assayed by liberation of thiopyridyl group during the reaction) and 1 to 6 maleimido groups (as determined by reaction with 3-mercaptoethanol). Conjugates containing 1 to 6 maytansinoid molecules per antibody molecule were prepared by this method, as calculated from absorbances at 252 and 280 nm, using extinction coefficients of $E_{280} = 5700 M^{-1}cm^{-1}$ and $E_{252} = 28044 M^{-1}cm^{-1}$ for drug and $E_{280} = 224000 M^{-1}cm^{-1}$ and $E_{252} = 87360 M^{-1}cm^{-1}$ for antibody.

Cells and Cell Culture. Human cell lines SK-BR-3 (HTB 30), Namalwa (CRL 1432), KB (CCL 17), SW-620 (CCL 227), A-498 (HTB 44), HT-29 (HTB 38), NIH:Ovar-3 (HTB 161), and LoVo (CCL 229) were purchased from the American Type Culture Collection (Rockville, MD).

Cytotoxicity Assays. The methods for the determination of the surviving fractions of adherent and nonadherent cell cultures (by colony-forming ability and by back-extrapolation of the exponential growth curves) have been described previously (19, 20).

Pharmacological Studies. Four mice were given injections i.v. of 2 mg/kg (by antibody) of the A7-SS-May conjugate. The volume of the
RESULTS AND DISCUSSION

We have chosen a highly cytotoxic drug, maytansine, for the preparation of immunoconjugates. Maytansine kills cells by interfering with the formation of microtubules and depolymerization of already formed microtubules (21). In vitro screening revealed that maytansine (1) (21, 22) is about 100- to 1000-fold more toxic for a range of human cancer cell lines than are most other anticancer drugs. For example, maytansine is highly cytotoxic for Namalwa cells (Fig. 1), with an IC50 of 4 x 10^-10 \text{ M}. Despite this high potency, maytansine was ineffective in human clinical trials (23) because of its high systemic toxicity, which resulted in a low therapeutic index. We reasoned that the nonspecific toxicity of maytansine could be lowered and the therapeutic index increased by the targeted delivery of this drug in conjugated form. In order to exploit the cytotoxic potential of maytansine in the conjugate, however, it is necessary to release the drug at the target cell in fully active form.

Two types of cleavable linkers have been widely used in the preparation of antibody-drug conjugates: acid-labile linkers (24-28) and peptidase-sensitive linkers (29). However, with few exceptions (30, 31), the cytotoxic potency of the resulting conjugates for cultured cell lines is very low, much lower than the cytotoxicity of the unconjugated drug, suggesting that internalization and release of drug molecules from these conjugates is inefficient. In addition, release into the medium of even a small fraction of a potent drug from a relatively nonpotent conjugate abolishes any hope of a specific cytotoxic effect. Internalization processes are poorly understood and difficult to influence, but the release of drugs may be improved by changing the design of the linker between the drug candidate and the antibody molecule.

On the basis of the promising results that have been obtained with antibody-toxin conjugates, where the conjugating linkage is a disulfide bond (5), we asked whether disulfide linkers would produce antibody-maytansinoid conjugates of comparable potency. Methotrexate linked to poly-d-lysine is the only reported drug conjugate where cleavage of a disulfide bond between the toxic and the targeting moiety releases the active drug, but this is only moderately cytotoxic (32). To obtain a highly cytotoxic drug that has a thiol “handle,” we have synthesized a new maytansinoid, 2 (Fig. 2). This novel compound 2 contains a methyl disulfide group and is 3- to 10-fold more cytotoxic than native maytansine (Table 1). The corresponding thiol-containing derivative 3 is as cytotoxic (IC50 = 1 x 10^-11 \text{ M} for SK-BR-3 cells after a 24-h exposure) as the disulfide-containing derivative 2.

We therefore prepared antibody conjugates of the maytansinoids and their conjugation to antibodies. In order to generate antibody-drug conjugates the antibody was modified with SPDP (N-succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate) to introduce dithio-pyridyl groups, or with SMCC (succinimidyl-3-(2-pyridyldithio)-propionate) to introduce dithio-propyl groups, or with SMCC (succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate) to introduce maleimido groups. May-SS-Me 2 was reduced to May-SH 3 (see “Materials and Methods”) and reacted with the modified antibodies.
Table 1 Comparison of in vitro cytotoxicity of maytansine and May-SS-Mew

<table>
<thead>
<tr>
<th>Cell line</th>
<th>Maytansine IC_{50} (m)</th>
<th>May-SS-Mew IC_{50} (m)</th>
</tr>
</thead>
<tbody>
<tr>
<td>KB (human epidermoid cancer)</td>
<td>$3.4 	imes 10^{-11}$</td>
<td>$1.1 	imes 10^{-11}$</td>
</tr>
<tr>
<td>SK-BR-3 (human breast cancer)</td>
<td>$1.1 	imes 10^{-10}$</td>
<td>$1.1 	imes 10^{-11}$</td>
</tr>
<tr>
<td>SW-620 (human colon cancer)</td>
<td>$1.0 	imes 10^{-10}$</td>
<td>$9.0 	imes 10^{-12}$</td>
</tr>
<tr>
<td>A-498 (human renal cancer)</td>
<td>$1.0 	imes 10^{-10}$</td>
<td>$1.0 	imes 10^{-10}$</td>
</tr>
<tr>
<td>NIH-Ovar-3 (human ovarian cancer)</td>
<td>$1.0 	imes 10^{-10}$</td>
<td>$5.0 	imes 10^{-11}$</td>
</tr>
<tr>
<td>HT-29 (human colon cancer)</td>
<td>ND*</td>
<td>$2.5 	imes 10^{-11}$</td>
</tr>
<tr>
<td>LoVo (human colon cancer)</td>
<td>ND*</td>
<td>$4.0 	imes 10^{-11}$</td>
</tr>
</tbody>
</table>

* Cytotoxicity of these drugs at different concentrations has been measured after a 24-h exposure of cells to the drugs, using a clonogenic assay, and log of surviving fractions versus drug concentration plots have been generated similar to the plots shown in Fig. 3c. Values for IC_{50} were determined from these plots.

\* After a 72-h exposure.
\* ND, not done.

The specific cytotoxicity of TA.1(-SS-May) was tested in vitro on the human breast cancer cell line SK-BR-3, which expresses $3 \times 10^6$ neu surface antigens per cell. Exposure of the target cells for 24 h to various concentrations of the drug conjugate showed a concentration-dependent cytotoxic effect, with an IC_{50} of $1.0 \times 10^{-10}$ M (Fig. 3b), demonstrating that the drug conjugate achieved a degree of cytotoxicity similar to that of the free drug. The cytotoxic effect of TA.1(-SS-May) could be abolished by an excess of nonconjugated TA.1 antibody, indicating that the killing of cells depends upon the specific antibody-antigen interaction. In addition, this conjugate was at least 1000-fold less cytotoxic towards neu-negative KB cells (Fig. 3b).

The cytotoxicity of TA.1(-SS-May) conjugates (where $n$ is an average number of maytansinoid molecules per antibody) could be increased by linking more drug molecules per antibody molecule, and it reached its maximum value at $n = 4$ (Table 2). Treatment of SK-BR-3 cells with TA.1(-SS-May)$_4$, for 72 h was even more effective in killing cells (IC_{50} = $3 \times 10^{-12}$ M; 99.9% of cells were killed at 0.1 nM concentration; Fig. 3c). Again, the cytotoxicity of TA.1(-SS-May)$_4$ could be abolished by an excess of nonconjugated TA.1 antibody. Also, the cytotoxicity of anti-B4(-SS-May)$_4$, a conjugate with an antibody of the same isotype but that does not bind to the target cells, was more than 300-fold lower with an IC_{50} greater than $1 \times 10^{-9}$ M (Fig. 3c). A TA.1-May conjugate in which the drug molecules are linked via a noncleavable thioether bond was 200-fold less potent under the same conditions (Fig. 3c). Similar results have been obtained with maytansinoid conjugates of the A7 antibody (16 directed against human colon cancer cell lines (Fig. 3d), and the antibody 5E9 directed against the human transferrin receptor (data not shown).

Pharmacological studies in mice showed that, following an i.v. injection, A7(-SS-May)$_4$ is cleared slowly from the blood of mice (Fig. 4). The difference in the time course of clearance of the maytansinoid moiety of the conjugate and the antibody moiety of the conjugate indicates that the conjugate slowly dissociates. Free drug is then quickly cleared (in a separate experiment we determined that the half-life for maytansine in the circulation is less than 20 min, data not shown). An alternative explanation is that the fraction of the conjugate that contains more drug molecules per antibody is cleared faster than the rest of the conjugate. We are currently developing a more stable disulfide-containing linker.

The conjugate A7(-SS-May)$_4$ was not toxic for the animals: 8 of 8 mice survived when given a dose of 8 mg/kg (by antibody) of the maytansinoid conjugate (containing 200 μg/kg of maytansine).
ACKNOWLEDGMENTS

We are grateful to Dr. Emil Frei III (Dana-Farber Cancer Institute) for helping us to procure maytansinoid. We wish to thank Takeda Chemical Industries of Japan for a generous supply of Ansamitocin P-3. We also wish to thank Dr. Takahashi (Kyoto University, Kyoto, Japan) for a sample of the antibody A7. We would like to thank our colleagues at ImmunoGen, Diane Yachimiak, Gail Raymond, Dr. Sergey Preobrazhensky, Patricia Halloran, and Arihka Moses for technical assistance, Mary Hoffie and Susan Camper for generating the anti-maytansinoid monoclonal antibody, and Drs. John M. Lambert and Albert Collinson for helpful discussions and comments on the manuscript.


Immonoconjugates Containing Novel Maytansinoids: Promising Anticancer Drugs


Updated version: Access the most recent version of this article at: [http://cancerres.aacrjournals.org/content/52/1/127](http://cancerres.aacrjournals.org/content/52/1/127)

E-mail alerts: Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions: To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions: To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.